Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Edwards Lifesciences CorpEW · Entity 3026 | CVP,Strategy/Corp Development | May 27, 2026 | May 27, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Edwards Lifesciences Corp
Report date May 27, 2026 · Filed May 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 98,611 |
Reported balance
After 2026-05-27 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-05-27 · Sale · Disposed 23,145 · Balance 98,611 F1: This transaction was executed in multiple trades at prices ranging from $86.27 to $86.57. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. |
| Common StockSEC Table I · non-derivative | Direct | 22,798.2532 |
Reported balance
Holding disclosure · report date 2026-05-27 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 22,798.2532 |
| Common StockSEC Table I · non-derivative | Indirect401(k) | 30,969.5756 |
Reported balance
Holding disclosure · report date 2026-05-27 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 30,969.5756 |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was executed in multiple trades at prices ranging from $86.27 to $86.57. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 04, 2017 Filed Aug 8, 2017 21:44 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 25,000 | $35.79 | $894,625.00 |
DisclosureSEC source: 0001225208-17-013379 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP, Heart Valve Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,608.1926 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person; and it includes 60,479 shares previously owned directly which are now owned by trust. Read SEC document |
| July 28, 2017 Filed Aug 1, 2017 21:38 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 5,300 | $0.00 Strike: $44.62 | $0.00 |
DisclosureSEC source: 0001225208-17-013087 · doc4.xml · derivative · entry 7 BOBO DONALD E JR · CIK 0001196661 · CVP, Heart Valve Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,400 Underlying: Common Stock · 5,300 shares Expires 2018-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 25, 2017. Read SEC document |
| July 28, 2017 Filed Aug 1, 2017 21:38 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 2,500 | $114.16 | $285,394.00 |
DisclosureSEC source: 0001225208-17-013087 · doc4.xml · nonDerivative · entry 4 BOBO DONALD E JR · CIK 0001196661 · CVP, Heart Valve Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,239.1926 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 25, 2017. F5 · price: This transaction was executed in multiple trades at prices ranging from $113.58 to $114.51. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. This amount includes quarterly acquisition of shares under the Edwards Lifesciences Corporation Employee Stock Purchase Plan as reflected on the most recent report of the plan administrator. Read SEC document |
| July 28, 2017 Filed Aug 1, 2017 21:38 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 2,500 | $115.05 | $287,626.50 |
DisclosureSEC source: 0001225208-17-013087 · doc4.xml · nonDerivative · entry 3 BOBO DONALD E JR · CIK 0001196661 · CVP, Heart Valve Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,739.1926 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 25, 2017. F4 · price: This transaction was executed in multiple trades at prices ranging from $114.63 to $115.5950. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. This amount includes quarterly acquisition of shares under the Edwards Lifesciences Corporation Employee Stock Purchase Plan as reflected on the most recent report of the plan administrator. Read SEC document |
| July 28, 2017 Filed Aug 1, 2017 21:38 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 300 | $115.86 | $34,759.02 |
DisclosureSEC source: 0001225208-17-013087 · doc4.xml · nonDerivative · entry 2 BOBO DONALD E JR · CIK 0001196661 · CVP, Heart Valve Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,239.1926 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 25, 2017. F3 · price: This transaction was executed in multiple trades at prices ranging from $115.69 to $115.98. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. This amount includes quarterly acquisition of shares under the Edwards Lifesciences Corporation Employee Stock Purchase Plan as reflected on the most recent report of the plan administrator. Read SEC document |
| July 28, 2017 Filed Aug 1, 2017 21:38 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 5,300 | $44.62 | $236,459.50 |
DisclosureSEC source: 0001225208-17-013087 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP, Heart Valve Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,539.1926 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 25, 2017. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. This amount includes quarterly acquisition of shares under the Edwards Lifesciences Corporation Employee Stock Purchase Plan as reflected on the most recent report of the plan administrator. Read SEC document |
| June 29, 2017 Filed Jul 3, 2017 20:05 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 5,600 | $0.00 Strike: $44.62 | $0.00 |
DisclosureSEC source: 0001225208-17-011948 · doc4.xml · derivative · entry 6 BOBO DONALD E JR · CIK 0001196661 · CVP, Heart Valve Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,700 Underlying: Common Stock · 5,600 shares Expires 2018-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 25, 2017. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| June 29, 2017 Filed Jul 3, 2017 20:05 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 3,000 | $116.89 | $350,673.60 |
DisclosureSEC source: 0001225208-17-011948 · doc4.xml · nonDerivative · entry 3 BOBO DONALD E JR · CIK 0001196661 · CVP, Heart Valve Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,182.6555 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 25, 2017. F4 · price: This transaction was executed in multiple trades at prices ranging from $116.20 to $117.19. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| June 29, 2017 Filed Jul 3, 2017 20:05 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 2,600 | $117.45 | $305,360.90 |
DisclosureSEC source: 0001225208-17-011948 · doc4.xml · nonDerivative · entry 2 BOBO DONALD E JR · CIK 0001196661 · CVP, Heart Valve Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,182.6555 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 25, 2017. F3 · price: This transaction was executed in multiple trades at prices ranging from $117.20 to $117.91. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| June 29, 2017 Filed Jul 3, 2017 20:05 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 5,600 | $44.62 | $249,844.00 |
DisclosureSEC source: 0001225208-17-011948 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP, Heart Valve Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,782.6555 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 25, 2017. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| May 11, 2017 Filed May 15, 2017 21:18 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantPerformance Rights · Derivative | 3,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-009778 · doc4.xml · derivative · entry 5 BOBO DONALD E JR · CIK 0001196661 · CVP, Heart Valve Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,625 Underlying: Common Stock · 3,625 shares Expires not disclosed F5 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 11, 2017 and scheduled to vest on May 11, 2020. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award. F5 · shares: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 11, 2017 and scheduled to vest on May 11, 2020. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award. F5 · derivative.exercise_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 11, 2017 and scheduled to vest on May 11, 2020. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award. F5 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 11, 2017 and scheduled to vest on May 11, 2020. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award. F5 · derivative.underlying_shares: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 11, 2017 and scheduled to vest on May 11, 2020. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| May 11, 2017 Filed May 15, 2017 21:18 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantEmployee Stock Option (Right to Acquire) · Derivative | 28,500 | $0.00 Strike: $110.25 | $0.00 |
DisclosureSEC source: 0001225208-17-009778 · doc4.xml · derivative · entry 4 BOBO DONALD E JR · CIK 0001196661 · CVP, Heart Valve Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,500 Underlying: Common Stock · 28,500 shares Expires 2024-05-10 F4 · derivative.exercise_date: These options were granted on May 11, 2017 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one month after the grant date in 36 equal monthly installments. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| May 11, 2017 Filed May 15, 2017 21:18 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 2,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-009778 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP, Heart Valve Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,182.6555 F1 · shares: These restricted stock units were granted on May 11, 2017 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become 50% vested three years after the grant date and 50% vested four years after the grant date. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| May 10, 2017 Filed May 12, 2017 23:12 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionPerformance Rights · Derivative | 10,850 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-009629 · doc4.xml · derivative · entry 5 BOBO DONALD E JR · CIK 0001196661 · CVP, Heart Valve Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,850 shares Expires 2017-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On May 8, 2014, the Reporting Person was granted a target number of shares (6,200) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 10, 2017, 175% of the target shares vested and were issued, and the actual number of shares vested are reflected on this Form. F1 · shares: On May 8, 2014, the Reporting Person was granted a target number of shares (6,200) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 10, 2017, 175% of the target shares vested and were issued, and the actual number of shares vested are reflected on this Form. F1 · price: On May 8, 2014, the Reporting Person was granted a target number of shares (6,200) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 10, 2017, 175% of the target shares vested and were issued, and the actual number of shares vested are reflected on this Form. F1 · derivative.exercise_date: On May 8, 2014, the Reporting Person was granted a target number of shares (6,200) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 10, 2017, 175% of the target shares vested and were issued, and the actual number of shares vested are reflected on this Form. F1 · derivative.underlying_shares: On May 8, 2014, the Reporting Person was granted a target number of shares (6,200) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 10, 2017, 175% of the target shares vested and were issued, and the actual number of shares vested are reflected on this Form. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| May 10, 2017 Filed May 12, 2017 23:12 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 5,662 | $110.58 | $626,103.96 |
DisclosureSEC source: 0001225208-17-009629 · doc4.xml · nonDerivative · entry 2 BOBO DONALD E JR · CIK 0001196661 · CVP, Heart Valve Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,282.6555 F1 · shares: On May 8, 2014, the Reporting Person was granted a target number of shares (6,200) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 10, 2017, 175% of the target shares vested and were issued, and the actual number of shares vested are reflected on this Form. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| May 10, 2017 Filed May 12, 2017 23:12 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 10,850 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-009629 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP, Heart Valve Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,944.6555 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On May 8, 2014, the Reporting Person was granted a target number of shares (6,200) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 10, 2017, 175% of the target shares vested and were issued, and the actual number of shares vested are reflected on this Form. F1 · price: On May 8, 2014, the Reporting Person was granted a target number of shares (6,200) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 10, 2017, 175% of the target shares vested and were issued, and the actual number of shares vested are reflected on this Form. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| May 08, 2017 Filed May 9, 2017 23:07 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 9,100 | $0.00 Strike: $44.62 | $0.00 |
DisclosureSEC source: 0001225208-17-009436 · doc4.xml · derivative · entry 8 BOBO DONALD E JR · CIK 0001196661 · CVP, Heart Valve Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,300 Underlying: Common Stock · 9,100 shares Expires 2018-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| May 08, 2017 Filed May 9, 2017 23:07 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 9,100 | $110.17 | $1,002,514.24 |
DisclosureSEC source: 0001225208-17-009436 · doc4.xml · nonDerivative · entry 4 BOBO DONALD E JR · CIK 0001196661 · CVP, Heart Valve Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,094.6555 F3 · price: This transaction was executed in multiple trades at prices ranging from $110.00 to $110.79. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F1 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| May 08, 2017 Filed May 9, 2017 23:07 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 9,100 | $44.62 | $405,996.50 |
DisclosureSEC source: 0001225208-17-009436 · doc4.xml · nonDerivative · entry 3 BOBO DONALD E JR · CIK 0001196661 · CVP, Heart Valve Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,194.6555 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| May 05, 2017 Filed May 9, 2017 23:07 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 10,000 | $0.00 Strike: $44.62 | $0.00 |
DisclosureSEC source: 0001225208-17-009436 · doc4.xml · derivative · entry 7 BOBO DONALD E JR · CIK 0001196661 · CVP, Heart Valve Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,400 Underlying: Common Stock · 10,000 shares Expires 2018-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| May 05, 2017 Filed May 9, 2017 23:07 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 10,000 | $110.50 | $1,104,997.00 |
DisclosureSEC source: 0001225208-17-009436 · doc4.xml · nonDerivative · entry 2 BOBO DONALD E JR · CIK 0001196661 · CVP, Heart Valve Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,094.6555 F2 · price: This transaction was executed in multiple trades at prices ranging from $110.02 to $110.81. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F1 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| May 05, 2017 Filed May 9, 2017 23:07 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 10,000 | $44.62 | $446,150.00 |
DisclosureSEC source: 0001225208-17-009436 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP, Heart Valve Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,094.6555 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| May 04, 2017 Filed May 4, 2017 23:59 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 10,000 | $0.00 Strike: $44.62 | $0.00 |
DisclosureSEC source: 0001225208-17-009195 · doc4.xml · derivative · entry 14 BOBO DONALD E JR · CIK 0001196661 · CVP, Heart Valve Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,400 Underlying: Common Stock · 10,000 shares Expires 2018-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| May 04, 2017 Filed May 4, 2017 23:59 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 10,000 | $110.27 | $1,102,681.00 |
DisclosureSEC source: 0001225208-17-009195 · doc4.xml · nonDerivative · entry 8 BOBO DONALD E JR · CIK 0001196661 · CVP, Heart Valve Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,094.6555 F6 · price: This transaction was executed in multiple trades at prices ranging from $110.60 to $110.60. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F1 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| May 04, 2017 Filed May 4, 2017 23:59 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 10,000 | $44.62 | $446,150.00 |
DisclosureSEC source: 0001225208-17-009195 · doc4.xml · nonDerivative · entry 7 BOBO DONALD E JR · CIK 0001196661 · CVP, Heart Valve Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,094.6555 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| May 03, 2017 Filed May 4, 2017 23:59 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 18,720 | $0.00 Strike: $25.48 | $0.00 |
DisclosureSEC source: 0001225208-17-009195 · doc4.xml · derivative · entry 13 BOBO DONALD E JR · CIK 0001196661 · CVP, Heart Valve Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,720 shares Expires 2017-05-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 28, 2016. F1 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| May 03, 2017 Filed May 4, 2017 23:59 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 400 | $0.00 Strike: $44.62 | $0.00 |
DisclosureSEC source: 0001225208-17-009195 · doc4.xml · derivative · entry 12 BOBO DONALD E JR · CIK 0001196661 · CVP, Heart Valve Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,400 Underlying: Common Stock · 400 shares Expires 2018-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| May 03, 2017 Filed May 4, 2017 23:59 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 13,720 | $109.72 | $1,505,400.93 |
DisclosureSEC source: 0001225208-17-009195 · doc4.xml · nonDerivative · entry 6 BOBO DONALD E JR · CIK 0001196661 · CVP, Heart Valve Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,094.6555 F3 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 28, 2016. F5 · price: This transaction was executed in multiple trades at prices ranging from $109.28 to $110.15. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F1 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| May 03, 2017 Filed May 4, 2017 23:59 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 400 | $110.10 | $44,039.00 |
DisclosureSEC source: 0001225208-17-009195 · doc4.xml · nonDerivative · entry 5 BOBO DONALD E JR · CIK 0001196661 · CVP, Heart Valve Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,814.6555 F4 · price: This transaction was executed in multiple trades at prices ranging from $110.03 to $110.15. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F1 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| May 03, 2017 Filed May 4, 2017 23:59 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 400 | $44.62 | $17,846.00 |
DisclosureSEC source: 0001225208-17-009195 · doc4.xml · nonDerivative · entry 4 BOBO DONALD E JR · CIK 0001196661 · CVP, Heart Valve Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,214.6555 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| May 03, 2017 Filed May 4, 2017 23:59 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 18,720 | $25.48 | $476,985.60 |
DisclosureSEC source: 0001225208-17-009195 · doc4.xml · nonDerivative · entry 3 BOBO DONALD E JR · CIK 0001196661 · CVP, Heart Valve Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,814.6555 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 28, 2016. F1 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| May 02, 2017 Filed May 4, 2017 23:59 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 10,000 | $0.00 Strike: $44.62 | $0.00 |
DisclosureSEC source: 0001225208-17-009195 · doc4.xml · derivative · entry 11 BOBO DONALD E JR · CIK 0001196661 · CVP, Heart Valve Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,800 Underlying: Common Stock · 10,000 shares Expires 2018-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| May 02, 2017 Filed May 4, 2017 23:59 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 10,000 | $110.05 | $1,100,540.00 |
DisclosureSEC source: 0001225208-17-009195 · doc4.xml · nonDerivative · entry 2 BOBO DONALD E JR · CIK 0001196661 · CVP, Heart Valve Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,094.6555 F2 · price: This transaction was executed in multiple trades at prices ranging from $110.00 to $110.39. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. F1 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| May 02, 2017 Filed May 4, 2017 23:59 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 10,000 | $44.62 | $446,150.00 |
DisclosureSEC source: 0001225208-17-009195 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP, Heart Valve Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,094.6555 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| April 05, 2017 Filed Apr 6, 2017 01:27 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 18,720 | $0.00 Strike: $25.48 | $0.00 |
DisclosureSEC source: 0001225208-17-007698 · doc4.xml · derivative · entry 6 BOBO DONALD E JR · CIK 0001196661 · CVP, Heart Valve Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,720 Underlying: Common Stock · 18,720 shares Expires 2017-05-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 28, 2016. F5 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| April 05, 2017 Filed Apr 6, 2017 01:27 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 13,520 | $93.57 | $1,265,054.23 |
DisclosureSEC source: 0001225208-17-007698 · doc4.xml · nonDerivative · entry 3 BOBO DONALD E JR · CIK 0001196661 · CVP, Heart Valve Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,094.6555 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 28, 2016. F3 · price: This transaction was executed in multiple trades at prices ranging from $93.02 to $93.99. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. This amount includes quarterly acquisition of shares under the Edwards Lifesciences Corporation Employee Stock Purchase Plan as reflected on the most recent report of the plan administrator. Read SEC document |
| April 05, 2017 Filed Apr 6, 2017 01:27 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 200 | $94.43 | $18,886.00 |
DisclosureSEC source: 0001225208-17-007698 · doc4.xml · nonDerivative · entry 2 BOBO DONALD E JR · CIK 0001196661 · CVP, Heart Valve Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,614.6555 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 28, 2016. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. This amount includes quarterly acquisition of shares under the Edwards Lifesciences Corporation Employee Stock Purchase Plan as reflected on the most recent report of the plan administrator. Read SEC document |
| April 05, 2017 Filed Apr 6, 2017 01:27 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 18,720 | $25.48 | $476,985.60 |
DisclosureSEC source: 0001225208-17-007698 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP, Heart Valve Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,814.6555 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 28, 2016. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. This amount includes quarterly acquisition of shares under the Edwards Lifesciences Corporation Employee Stock Purchase Plan as reflected on the most recent report of the plan administrator. Read SEC document |
| March 06, 2017 Filed Mar 7, 2017 21:18 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 18,720 | $0.00 Strike: $25.48 | $0.00 |
DisclosureSEC source: 0001225208-17-005737 · doc4.xml · derivative · entry 7 BOBO DONALD E JR · CIK 0001196661 · CVP, Heart Valve Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,440 Underlying: Common Stock · 18,720 shares Expires 2017-05-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 28, 2016. F1 · balance_after: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 28, 2016. Read SEC document |
| March 06, 2017 Filed Mar 7, 2017 21:18 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 10,920 | $89.81 | $980,740.49 |
DisclosureSEC source: 0001225208-17-005737 · doc4.xml · nonDerivative · entry 4 BOBO DONALD E JR · CIK 0001196661 · CVP, Heart Valve Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,900.5147 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 28, 2016. F5 · price: This transaction was executed in multiple trades at prices ranging from $89.28 to $90.24. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| March 06, 2017 Filed Mar 7, 2017 21:18 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 2,600 | $90.69 | $235,800.24 |
DisclosureSEC source: 0001225208-17-005737 · doc4.xml · nonDerivative · entry 3 BOBO DONALD E JR · CIK 0001196661 · CVP, Heart Valve Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,820.5147 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 28, 2016. F4 · price: This transaction was executed in multiple trades at prices ranging from $90.35 to $91.19. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| March 06, 2017 Filed Mar 7, 2017 21:18 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 200 | $91.69 | $18,338.00 |
DisclosureSEC source: 0001225208-17-005737 · doc4.xml · nonDerivative · entry 2 BOBO DONALD E JR · CIK 0001196661 · CVP, Heart Valve Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,420.5147 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 28, 2016. F3 · price: This transaction was executed in multiple trades at prices ranging from $91.52 to $91.86. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| March 06, 2017 Filed Mar 7, 2017 21:18 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 18,720 | $25.48 | $476,985.60 |
DisclosureSEC source: 0001225208-17-005737 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP, Heart Valve Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,620.5147 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 28, 2016. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| February 06, 2017 Filed Feb 8, 2017 21:16 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 18,720 | $0.00 Strike: $25.48 | $0.00 |
DisclosureSEC source: 0001225208-17-002652 · doc4.xml · derivative · entry 6 BOBO DONALD E JR · CIK 0001196661 · CVP, Heart Valve Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,160 Underlying: Common Stock · 18,720 shares Expires 2017-05-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 28, 2016. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| February 06, 2017 Filed Feb 8, 2017 21:16 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 11,600 | $89.23 | $1,035,086.56 |
DisclosureSEC source: 0001225208-17-002652 · doc4.xml · nonDerivative · entry 3 BOBO DONALD E JR · CIK 0001196661 · CVP, Heart Valve Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,900.5147 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 28, 2016. F4 · price: This transaction was executed in multiple trades at prices ranging from $88.76 to $89.75. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| February 06, 2017 Filed Feb 8, 2017 21:16 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 2,120 | $90.02 | $190,845.37 |
DisclosureSEC source: 0001225208-17-002652 · doc4.xml · nonDerivative · entry 2 BOBO DONALD E JR · CIK 0001196661 · CVP, Heart Valve Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,500.5147 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 28, 2016. F3 · price: This transaction was executed in multiple trades at prices ranging from $89.78 to $90.58. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| February 06, 2017 Filed Feb 8, 2017 21:16 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 18,720 | $25.48 | $476,985.60 |
DisclosureSEC source: 0001225208-17-002652 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP, Heart Valve Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,620.5147 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 28, 2016. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| January 12, 2017 Filed Jan 17, 2017 21:39 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 18,720 | $0.00 Strike: $25.48 | $0.00 |
DisclosureSEC source: 0001225208-17-001184 · doc4.xml · derivative · entry 6 BOBO DONALD E JR · CIK 0001196661 · CVP, Heart Valve Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,880 Underlying: Common Stock · 18,720 shares Expires 2017-05-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 28, 2016. F4 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| January 12, 2017 Filed Jan 17, 2017 21:39 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 8,320 | $97.69 | $812,757.50 |
DisclosureSEC source: 0001225208-17-001184 · doc4.xml · nonDerivative · entry 3 BOBO DONALD E JR · CIK 0001196661 · CVP, Heart Valve Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,900.5147 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 28, 2016. F5 · price: This transaction was executed in multiple trades at prices ranging from $97.56 to $97.86. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F4 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| January 12, 2017 Filed Jan 17, 2017 21:39 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 5,400 | $97.14 | $524,570.04 |
DisclosureSEC source: 0001225208-17-001184 · doc4.xml · nonDerivative · entry 2 BOBO DONALD E JR · CIK 0001196661 · CVP, Heart Valve Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,220.5147 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 28, 2016. F3 · price: This transaction was executed in multiple trades at prices ranging from $96.56 to $97.55. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F4 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.